Introduction When the COVID-19 pandemic struck no specific therapies were available and
many turned to COVID-19 convalescent plasma (CCP), a form of antibody therapy. The …

Importance Patients who are immunocompromised have increased risk for morbidity and
mortality associated with coronavirus disease 2019 (COVID-19) because they less …

Abstract Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the cause of
coronavirus disease 2019 (COVID-19), has incited a global health crisis. Currently, there are …

Background Inborn errors of immunity (IEIs) are considered significant challenges for
children with IEIs, their families, and their medical providers. Infections are the most common …

Understanding the mechanisms of antibody-mediated neutralization of SARS-CoV-2 is
critical in combating the COVID-19 pandemic. Based on previous reports of antibody …

Background A large number of studies have been carried out involving passive antibody
administration for the treatment and prophylaxis of COVID-19 and have shown variable …

Abstract Background and Objective During the COVID-19 pandemic, trials on convalescent
plasma (ConvP) were performed without preceding dose-finding studies. This study aimed …

Introduction When Coronavirus Disease-19 (COVID-19) struck the world in December 2019,
initiatives started to investigate the efficacy of convalescent plasma, a readily available …

Data on COVID-19 convalescent plasma (CCP) safety and efficacy in children and young
adults are limited. This single-center prospective, open-label trial evaluates CCP safety …

SARS-CoV-2 infection of immunocompromised individuals often leads to prolonged
detection of viral RNA and infectious virus in nasal specimens, presumably due to the lack of …